XSHG
600380
Market cap2.66bUSD
Jul 09, Last price
9.88CNY
1D
-0.20%
1Q
-11.39%
Jan 2017
9.90%
IPO
119.07%
Name
Joincare Pharmaceutical Group Industry Co Ltd
Chart & Performance
Notes
No notes on this company yet
Write a private note on this company, for your eyes only
Profile
Joincare Pharmaceutical Group Industry Co., Ltd. is a Chinese enterprise primarily focused on the comprehensive process of researching, developing, producing, and commercializing pharmaceutical and healthcare products within China. The company boasts a broad pharmaceutical portfolio that includes both Western chemical drug preparations, addressing conditions such as respiratory, gastrointestinal, anti-infection, gonadotropic, and psychiatric disorders, as well as traditional Chinese medicines (TCM), with offerings for anti-tumor and cold relief. Beyond finished drugs, Joincare supplies chemical active pharmaceutical ingredients (APIs) and intermediates. Its operations also extend into the diagnostics sector, where it provides specialized reagents and equipment, such as an autoimmunity multiple detection platform and an IgM diagnostic kit. Furthermore, the company markets a range of health and wellness products, exemplified by American ginseng tea and Jingxin menocare essence. Joincare diversifies its business by engaging in the wholesale and retail of personal care items, including skincare products, cosmetics, and various other essential goods. Its products are available in diverse formats, such as hormone tablets, oral liquid formulations, and standard tablets. Established in 1992, Joincare Pharmaceutical Group maintains its principal offices in Shenzhen, China.
Valuation
Title CNY in thousands, except ratios and share amounts | FY | FY | FY | FY | FY | FY | FY | FY | FY | FY |
|---|---|---|---|---|---|---|---|---|---|---|
| 2025‑12 | 2024‑12 | 2023‑12 | 2022‑12 | 2021‑12 | 2020‑12 | 2019‑12 | 2018‑12 | 2017‑12 | 2016‑12 | |
| Income | ||||||||||
Revenues | ||||||||||
Cost of revenue | ||||||||||
Unusual Expense (Income) | ||||||||||
NOPBT | ||||||||||
NOPBT Margin | ||||||||||
Operating Taxes | ||||||||||
Tax Rate | ||||||||||
NOPAT | ||||||||||
Net income | ||||||||||
Dividends | ||||||||||
Dividend yield | ||||||||||
Proceeds from repurchase of equity | ||||||||||
BB yield | ||||||||||
| Debt | ||||||||||
Debt current | ||||||||||
Long-term debt | ||||||||||
Deferred revenue | ||||||||||
Other long-term liabilities | ||||||||||
Net debt | ||||||||||
| Cash flow | ||||||||||
Cash from operating activities | ||||||||||
CAPEX | ||||||||||
Cash from investing activities | ||||||||||
Cash from financing activities | ||||||||||
FCF | ||||||||||
| Balance | ||||||||||
Cash | ||||||||||
Long term investments | ||||||||||
Excess cash | ||||||||||
Stockholders' equity | ||||||||||
Invested Capital | ||||||||||
ROIC | ||||||||||
ROCE | ||||||||||
| EV | ||||||||||
Common stock shares outstanding | ||||||||||
Price | ||||||||||
Market cap | ||||||||||
EV | ||||||||||
EBITDA | ||||||||||
EV/EBITDA | ||||||||||
Interest | ||||||||||
Interest/NOPBT | ||||||||||